In fiscal 2026, which ended Feb 28, 2026, Medinotec Inc. generated $906,798 of cash from operations, up 3.3% from the year before. It spent $1,363 on capital expenditures. That left free cash flow of $905,435.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2027
Aug 31, 2026
|
FY 2026
Feb 28, 2026
|
FY 2025
Feb 28, 2025
|
FY 2024
Feb 29, 2024
|
FY 2023
Feb 28, 2023
|
|---|---|---|---|---|---|
| Operating | |||||
| Depreciation and amortization |
0
+170.3%
|
0
+9.5%
|
0
-16.3%
|
0
+64.7%
|
0
|
| Operating cash flow |
0
-45.6%
|
1
+3.3%
|
1
+6063.7%
|
0
+102.9%
|
-0
|
| Investing | |||||
| Capital expenditures |
0
|
0
-98.5%
|
0
+3847.4%
|
0
-95.9%
|
0
|
| Investing cash flow |
-0
|
-0
+98.5%
|
-0
-979.1%
|
0
+101.9%
|
-1
|
| Financing | |||||
| Debt issued |
—
|
—
|
—
|
—
|
0
|
| Financing cash flow |
—
|
-1
-9.9%
|
-1
-10953.9%
|
-0
-100.2%
|
4
|
| Change in cash | |||||
| Effect of exchange rate |
0
+262.7%
|
0
-2.3%
|
0
+290.8%
|
-0
-125.1%
|
0
|
| Net change in cash |
0
+165.9%
|
-0
+67.7%
|
-0
-111.5%
|
-0
-100.7%
|
3
|
| Free cash flow |
0
|
1
+14.8%
|
1
+6480.6%
|
0
+102.2%
|
-1
|
| Ratios | |||||
| Free cash flow margin |
2.97%
|
9.31%
|
8.66%
|
0.24%
|
-54.61%
|
| Capital expenditures to revenue |
0.69%
|
0.01%
|
0.98%
|
0.04%
|
5.53%
|
| Cash conversion |
0.63x
|
1.14x
|
0.41x
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- MDNC (OTC)
- Fiscal year ends
- February 28
- Incorporated in
- NV
- Headquarters
- Johannesburg
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1931055
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.